Related Experiment Video
Updated: Jun 19, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Micafungin - the newest echinocandin
Zelalem Temesgen1, Jason Barreto, Sandro Vento
1Mayo Clinic and Foundation, Division of Infectious Diseases, Rochester, MN 55905, USA. temesgen.zelalem@mayo.edu
Abstract:
Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it also has utility for the treatment of infections caused by Aspergillus species. However, its approved indications remain for the treatment of both invasive and esophageal candidiasis and for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. is generally well tolerated with few significant adverse effects.
Related Concept Videos
Antifungal Agents
Cryptococcal Meningitis
Candidiasis
Fungal Group Zygomycota
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Fungal Phylum Microsporidia
